5N Plus: Capitalizing on the Reshoring of Critical Mineral Supply Chains

Amar Pandya of PenderFund Capital Management presented his in-depth investment thesis on 5N Plus (Canada: VNP) at Best Ideas 2026.

Thesis summary:

5N Plus is a Montreal-based producer of advanced specialty semiconductors and performance materials, operating eight manufacturing facilities and four R&D centers across three continents. Amar notes that the company has successfully completed a multi-year transformation, exiting low-margin, commoditized metals trading businesses to focus on value-add, proprietary products. This strategic shift was designed to reduce earnings volatility by 50% and ensure profitability throughout the market cycle. By buying degraded resources and waste streams from smelters and refining them into high-purity inputs, 5N Plus has established a unique upstream moat that feeds its downstream manufacturing of engineered materials for high-growth industries.

The company operates through two primary segments: Specialty Semiconductors and Performance Materials. The latter produces bismuth-based APIs for pharmaceutical applications, such as Pepto-Bismol, and accounts for 25% of revenue with 53% gross margins. The Specialty Semiconductors segment, representing 75% of revenue, serves critical growth sectors including renewable energy and space infrastructure. Amar highlights the company’s vital role as a supplier to First Solar, which recently extended contracts to increase cadmium telluride delivery. Furthermore, the 2021 acquisition of AZUR has positioned the firm as a leader in multi-junction solar cells for satellites, with production capacity nearly sold out through 2029.

Amar emphasizes that 5N Plus is a primary beneficiary of rising geopolitical tensions and the resulting push for Western-based supply chains. As one of the few large-scale suppliers of critical minerals outside of China, the company faces limited direct competition for its proprietary products. High barriers to entry, including elevated capital requirements and multi-year qualification periods, further protect its market position. The company also possesses several “moonshot” opportunities not yet reflected in the share price, including photon-counting X-ray detectors, a partnership for concentrated solar storage with Raygen, and an equity stake in Microbion for novel antimicrobial drugs.

Management, led by incoming CEO Richard Perron, maintains a disciplined approach to capital allocation, favoring accretive M&A of proprietary businesses where the product represents a small fraction of the end customer’s total cost. This provides the company with pricing power and the ability to pass on inflationary costs. The balance sheet is robust, with a net debt-to-EBITDA ratio of 0.8x and strong FCF generation. Amar expects the company to achieve 80% EBITDA growth between 2024 and 2027, supported by a record backlog and the rolling off of less profitable legacy contracts.

The shares recently traded at $17.72, representing a market capitalization of $1.58 billion and an EV of $1.64 billion. Amar suggests the stock is attractively valued at 12.5x 2025A EV/EBITDA, a discount to its global peer group despite its higher growth profile and strategic importance. His base case valuation of $30 per share assumes 16% revenue growth and 15x EBITDA, while a 2027 target price of $29.40 implies approximately 65% upside from recent levels. This valuation excludes the potential $1.62 per share in present value from hidden assets and the impact of future accretive M&A, which Amar views as additional optionality.

The full session is available exclusively to members of MOI Global.

Members, log in below to access the full session.

Not a member?

Thank you for your interest.  Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:

First name:

Last name:

Email address:

City / state / country:

Company:

How did you hear about MOI Global? Select Member referral Staff This website Media / Internet Other

If referral, please provide member's name:

Which of the following applies most closely to you? Select Investment Firm - Head Investment Firm - Analyst or PM Institutional Allocator - Firm C-Level Executive Institutional Allocator - Firm Employee Family Office - Head or Co-Owner Family Office - Employee Non-Investment Firm - C-Level Executive Non-Investment Firm - Employee Other

How do you hope to add value to the community?

Leave this field empty if you're human:

About the instructor:

Amar Pandya is the Portfolio Manager of the Pender Alternative Arbitrage Fund, Pender Alternative Arbitrage Plus Fund and the Pender Alternative Special Situations Fund. He joined PenderFund Capital Management in October 2017.

Amar began his investment career in 2011 in the Portfolio Management Training Program at a large global financial services company. He moved to pursue his passion for equities becoming an Associate Portfolio Manager at a large-cap equity value firm before being drawn to Pender and the west coast in 2017.

As an advocate of a contrarian value investing approach, Amar works to identify out of favour, high quality compound growth businesses, as well as opportunistic close-the-discount investment opportunities trading at a significant discount to intrinsic value. He has also developed an expertise in event driven special situations with a primary focus on M&A and balance sheet driven special situations. Amar has researched and uncovered many such opportunities which have contributed to Pender’s equity mandates.

Amar holds a Bachelor of Commerce degree in Finance (Honours) from the University of Manitoba. He earned his Chartered Financial Analyst designation in 2015. He is actively involved with CFA Society Vancouver where he serves as co-chair of the CFA Vancouver Programs Committee.